brolucizumab

Ligand id: 8713

Name: brolucizumab

References
1. Borras L, Urech D, Gunde T. (2013)
Stable and soluble antibodies inhibiting VEGF.
Patent number: US8349322 B2. Assignee: ESBATech, an Alcon Biomedical Research Unit, LLC.. Priority date: 25/06/2008. Publication date: 08/01/2013.
2. Borras L, Urech D. (2012)
Humanization of rabbit antibodies using a universal antibody framework.
Patent number: US8293235 B2. Assignee: ESBATech, an Alcon Biomedical Research Unit, LLC.. Priority date: 25/06/2008. Publication date: 23/10/2012.
3. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG et al.. (2019)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology, [Epub ahead of print]. [PMID:30986442]
4. Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. (2018)
Biosimilars in ophthalmology: "Is there a big change on the horizon?".
Clin Ophthalmol, 12: 2137-2143. [PMID:30498330]